Why Patient Engagement Matters in HCV

Last week we published a literature review of economic models published on new hepatitis C virus (HCV) treatments over the...

Finding the Right Comparison

Recently, I had the opportunity to work with two strong pharmacoeconomics researchers (Daniel Mullins and Julia Slejko) to develop a...

#PharmEconFriday: The Markov Model

#PharmEconFriday: The Markov Model

Over the next few years, my career will shift focus to pharmacoeconomics (#PharmEcon) research and further away from pharmacy management...

Merck Joins the Once-Daily Hep C Party

Merck Joins the Once-Daily Hep C Party

It was announced this week that the Food and Drug Administration (FDA) has officially approved Merck’s new once-daily regimen to...

Drug Price Wars, Episode I: The High Priced Hep C Menace

Drug Price Wars, Episode I: The High Priced Hep C Menace

On December 22, 2014 Express Scripts (ESRX) announced to the public that it had reached a deal with AbbVie (ABBV),...

All original content on these pages is fingerprinted and certified by Digiprove